A Democratic bill with 1 Republican cosponsor · See the cosponsor
Last activity — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The Medication Competition Act requires the Secretary of Health and Human Services to determine exclusivity periods for licensed biological products. It amends the Public Health Service Act to include specific requirements for listing these periods. The bill establishes different timelines for products licensed before or after the date of enactment. Specifically, it mandates how the Secretary must publish exclusivity periods for both first interchangeable biological products and reference products. This ensures that the Secretary includes expiration dates on published lists within specific timeframes.
Yes· 3 of 5
- Scored +4
Does this make what the government does easier for the public to see?
The bill mandates specific timelines for the Secretary of Health and Human Services to publish expiration dates for biological product exclusivity.
- Scored +3
Does this give people more protection from unfair business practices?
The bill increases transparency regarding biological product exclusivity periods, which can assist in market competition and consumer awareness.
- Scored +2
Would households on low incomes be better off under this?
Increased transparency in biological product exclusivity can lead to greater market competition and lower drug costs for consumers.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Transparency for Biological Products: The bill requires the Secretary to include applicable exclusivity periods on a published list for first interchangeable biological products (Section 2, (I)(aa) and (I)(bb)). This ensures that information regarding how long a product has exclusivity is made known once an expiration date can be known.
-
Timely Information for New Products: For biological products licensed on or after the date of enactment, the Secretary must include the expiration date of the exclusivity period for reference products not later than 30 days after licensure (Section 2, (II)(aa)). This provides quick access to expiration data for new products.
-
Systematic Updates for Existing Products: For products licensed before the enactment of this act, the Secretary is required to include the expiration date of exclusivity periods for reference products on the list within 2 years (Section 2, (II)(bb)). This ensures that older products are eventually integrated into the updated listing system.
Potential Negative Impacts for People
- No negative impacts or burdens are explicitly stated in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill mandates specific timelines for the Secretary of Health and Human Services to publish expiration dates for biological product exclusivity.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — Increased transparency in biological product exclusivity can lead to greater market competition and lower drug costs for consumers. Would people in cities be better off under this? — The bill facilitates information regarding medication competition which may benefit broad consumer populations.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill increases transparency regarding biological product exclusivity periods, which can assist in market competition and consumer awareness.
- Healthcare
- Does this lower the price of prescription medicines? — By providing clearer timelines for when exclusivity ends, the bill facilitates more timely entry of competitive biological products into the market.
- 4/16/2026
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 1 Cosponsor added.
- Introduced in Senate
Ted BuddRepublican · North Carolina